Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
阿里拉姆将在派杰投资第36届年度医疗会议上进行网络直播演讲
Nov 27, 2024
2024年11月27日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 27, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City.
马萨诸塞州剑桥市--（商业新闻）--2024年11月27日--阿里拉姆制药公司（纳斯达克：ALNY），领先的RNA干扰治疗公司，今天宣布管理层将于2024年12月5日星期四上午11:00在纽约市的纽约大饭店举行的派杰投资第36届年度医疗会议上进行公司资料的介绍。
A live audio webcast of the presentation will be available on the Investors section of the Company's website at . A replay will be available on the Alnylam website within 48 hours after the event.
该演讲的实时音频网络直播将可在公司的投资者网站上获得。活动结束后48小时内，阿里拉姆网站上将提供重播。
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
关于阿里拉姆制药
阿里拉姆制药公司（纳斯达克：ALNY）领导了RNA干扰（RNAi）向全新一类创新药物的转化，具有改变受罕见和普遍疾病困扰的人们生活的潜力，满足未满足的需求。 基于诺贝尔奖获奖科学，RNAi治疗代表着一种强大的、经过临床验证的方法，产生了变革性的药物。自2002年成立以来，阿里拉姆领导了RNAi革命，并继续实现将科学可能性变为现实的大胆愿景。阿里拉姆的商业RNAi治疗产品包括ONPATTRO（patirsiran）、AMVUTTRA（vutrisiran）、GIVLAARI（givosiran）、OXLUMO（lumasiran）和Leqvio（inclisiran），后者由阿里拉姆的合作伙伴诺华进行开发和商业化。阿里拉姆拥有一条深厚的研究药物管线，包括多个处于晚期开发阶段的产品候选者。阿里拉姆正在执行其 "Alnylam P5x25" 策略，以通过可持续创新和卓越的财务表现为全球患者提供转型药物，从而建立领先的生物技术形象。阿里拉姆总部位于马萨诸塞州剑桥市。如需了解更多有关我们的团队、科学和管线的信息，请访问并在X（前身为Twitter）上与我们互动，用户名为@Alnylam，或在LinkedIn、Facebook或者Instagram上与我们互动。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Alnylam Pharmaceuticals, Inc.
克莉丝汀·雷甘·林登布姆
（投资者和媒体）
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
乔什·布罗德斯基
（投资者）
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
来源：Alnylam Pharmaceuticals，Inc。
